Uzbekistan’s pharmaceutical industry & prospects for development: regarding what was done last year, and plans for the futur

 

The pharmaceutical industry is one of the important components of the healthcare system, and the level of development of this industry directly affects the quality of life of the population. In this regard, extensive work has been carried out in Uzbekistan in recent years to develop the pharmaceutical industry, writes Jamshid Akhmatov.

According to the Decree of the President of the Republic of Uzbekistan Shavkat Miromonovich Mirziyoyev (pictured)  “On additional measures to accelerate the development of the pharmaceutical industry of the Republic in 2022-2026“, the pharmaceutical industry has been granted a number of benefits, in particular:

state registration of new pharmaceutical products produced by domestic manufacturing organisations is carried out for an unlimited period;

domestic manufacturing organisations that have a certificate of Good Manufacturing Practice (GMP) and ISO:13485 are exempt from mandatory certification;

75% of the expenses of domestic manufacturing organisations for registration of pharmaceutical products in foreign countries are covered from the Fund for Support and Development of the Pharmaceutical Industry.

Moreover, within the framework of the Decree, in order to reduce the existing restrictions in the sphere, the following has been cancelled:

prohibition on the collection of donated blood and the production of pharmaceutical products based on it in private capacity;

restriction on the conducting of clinical trials of medicines on healthy volunteers;

restriction on the production of medicines having the same composition by one manufacturer under different trade names based on international brands.

The above mentioned benefits and preferences will allow to increase the volume of the pharmaceutical market. In particular, in 2022, the volume of the domestic market in the pharmaceutical sector of Uzbekistan amounted to $1.5 billion, 25% of which is provided by local production.

According to the Agency for the Development of the Pharmaceutical Industry, by the end of 2022, 212 pharmaceutical manufacturing enterprises are operating in the Republic. In particular, 87 of them specialise in the production of medicines, 38 in medical equipment, 87 in medical devices, and 142 pharmacies in the preparation of medicines.

In addition, there are 578 organisations engaged in wholesale sales, as well as 15,799 pharmacies and their branches engaged in the retail sale of medicines and medical products.

Production dynamics.

The implemented measures and the conditions created for the development of pharmaceuticals in recent years have begun to pay off. By the end of 2022, local enterprises produced pharmaceutical products totaling 4.12 trillion sums, and the volume of production increased by 14% compared to the same period in 2021. In particular, in January-November 2022, the volume of production of medicines containing penicillins, streptomycins or their derivatives increased by 24%, medicines containing alkaloids or their derivatives by 65%, as well as medical cotton wool, gauze and similar pharmaceuticals by almost 30%.

In 2022, 4 pharmaceutical enterprises were established, and the level of localisation of 284 medicines, 80 types of medical devices, 13 types of medical equipment, including medicines belonging to the groups of dentistry, oncology, toxicology and pulmonology, has increased.

REMEDY GROUP has mastered the production of “Antikovir” against COVID, ZUMA PHARMA has mastered the production of medicines “Enoxaparin” and “Insulin”, BETA UBK INTERNATIONAL has mastered the production of anti-oncological medicines in syringe pens for the first time. The TASH-BEL MED joint venture has launched the production of a new type of implants for traumatology and orthopedics. By the end of 2022, goods worth 2.2 billion sums were produced for products included in the localization program, the growth rate, compared to the plan, was 118%.

Significant progress has also been made in the implementation of international standards in 2022. According to the results of last year, 95 (45%) of 212 pharmaceutical enterprises operating in Uzbekistan have implemented international and national standards. The ISO 9001:2008 standard was implemented at 59 enterprises, the ISO 13485 international standard was implemented at 6 enterprises, the GMP standard was implemented at 28 (38 in total), the GDP standard was implemented at 30 enterprises and the GLP standard was implemented at 1 enterprise.

Foreign economic activity.

Most of the pharmaceutical market in Uzbekistan is still satisfied by imported products. Nevertheless, in 2022, as a result of an increase in local production, the total cost of importing pharmaceutical products decreased by almost 20% compared to 2021, and amounted to $1.3 billion. Pharmaceutical products are mainly imported from India, Latvia, Russia, Georgia, and the USA.

On the contrary, there was a significant increase in the volume of exports of pharmaceutical products. By the end of 2022, pharmaceutical products and services were exported in the amount of $150.61 million, the plan was fulfilled by 100.4%, compared with the forecast. In January-November 2022, the volume of exports of gauze and other textile medical equipment increased by 41%, and the volume of exports of medicines containing alkaloids or their derivatives increased by 24%. In addition, the geography of exports has been expanded from 34 to 39 countries. Last year, Ubeki medicines managed to enter the markets of such new countries as Yemen, Estonia, Slovakia, Poland and China.

Investment activity.

In 2022, within the framework of 42 investment projects included in the Decree of the President of the Republic of Uzbekistan “On additional measures to accelerate the development of the pharmaceutical industry of the Republic in 2022-2026“, $83.1 million (100% of the plan) of investment funds (including $33 million of direct investment) were disbursed. 372 new jobs were created as a result of the launch of 10 projects with a total cost of $31.9 million. In particular, in the Bukhara region, LLC Le Uat De Bukhara launched an enterprise for the production of medical gauze and cotton wool, and in Samarkand, a joint venture of LLC Samarkand England Eco-Medical implemented a project for the production of infusion solutions worth $9 million.

The industrial site of the innovative research and production pharmaceutical cluster Tashkent Pharma Park has been expanded and 7 investment projects worth $200.39 million have been implemented.

source - https://eutoday.net/uzbekistans-pharmaceutical-industry-prospects-for-development-regarding-what-was-done-last-year-and-plans-for-the-future/